WO2011005295A8 - Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto - Google Patents

Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto Download PDF

Info

Publication number
WO2011005295A8
WO2011005295A8 PCT/US2010/001803 US2010001803W WO2011005295A8 WO 2011005295 A8 WO2011005295 A8 WO 2011005295A8 US 2010001803 W US2010001803 W US 2010001803W WO 2011005295 A8 WO2011005295 A8 WO 2011005295A8
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
receptor
treatment
compounds
sphingosine
Prior art date
Application number
PCT/US2010/001803
Other languages
French (fr)
Other versions
WO2011005295A1 (en
Inventor
Robert M. Jones
Daniel J. Buzard
Thomas O. Schrader
Michelle Kasem
Xiuwen Zhu
Benjamin R. Johnson
Juerg Lehmann
Sangdon Han
Andrew M. Kawasaki
Original Assignee
Arena Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals, Inc. filed Critical Arena Pharmaceuticals, Inc.
Publication of WO2011005295A1 publication Critical patent/WO2011005295A1/en
Publication of WO2011005295A8 publication Critical patent/WO2011005295A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)

Abstract

The present invention relates to certain compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer.
PCT/US2010/001803 2009-06-24 2010-06-23 Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto WO2011005295A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26948309P 2009-06-24 2009-06-24
US61/269,483 2009-06-24

Publications (2)

Publication Number Publication Date
WO2011005295A1 WO2011005295A1 (en) 2011-01-13
WO2011005295A8 true WO2011005295A8 (en) 2012-09-20

Family

ID=42827301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/001803 WO2011005295A1 (en) 2009-06-24 2010-06-23 Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto

Country Status (1)

Country Link
WO (1) WO2011005295A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126932B2 (en) 2008-07-23 2015-09-08 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54970B1 (en) 2008-08-27 2016-11-30 Arena Pharm Inc Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
EP3378854B1 (en) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA2789480A1 (en) * 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
US9073931B2 (en) 2012-03-16 2015-07-07 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
SG11201405328SA (en) 2012-03-16 2014-11-27 Vitae Pharmaceuticals Inc Liver x receptor modulators
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
SI3310760T1 (en) 2015-06-22 2023-02-28 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta(b)indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders
MA47503A (en) 2017-02-16 2021-04-21 Arena Pharm Inc COMPOUNDS AND METHODS FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES OF THE INTESTINE WITH EXTRAINTESTINAL MANIFESTATIONS
KR20190116416A (en) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. Compounds and Methods for Treating Primary Bile Cholangitis
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE541830T1 (en) * 2004-12-13 2012-02-15 Ono Pharmaceutical Co AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICAL USE THEREOF
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Compounds
RS54970B1 (en) * 2008-08-27 2016-11-30 Arena Pharm Inc Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126932B2 (en) 2008-07-23 2015-09-08 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
US9522133B2 (en) 2008-07-23 2016-12-20 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders

Also Published As

Publication number Publication date
WO2011005295A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
WO2011005295A8 (en) Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
MX354134B (en) SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS.
EA201170374A1 (en) Derivatives of substituted tricyclic acids as agonists of the S1P1 receptor, used in the treatment of autoimmune and inflammatory diseases
ATE531711T1 (en) TETRAHYDROCYCLOPENTAÄBÜINDOL-3-YL CARBONIC ACID DERIVATIVES SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES
MX343383B (en) Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl }-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one.
CA2769553A1 (en) Novel pyrimidine and triazine hepcidin antagonists
NZ705135A (en) Heteroaryl compounds and methods of use thereof
PH12014502524A1 (en) Carboxylic acid compounds
MX2012008049A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof.
NZ603876A (en) Nitrogen heterocyclic compounds useful as pde10 inhibitors
GB2511685A (en) Muscarinic m1 receptor agonists
JO3327B1 (en) Z)-2-Cyano-3-hydroxy-but-2-enoic acid-(4’-trifluormethylphenyl)- amide tablet formulations with improved stability
MX2010009922A (en) Pyridazinone glucokinase activators.
CR20200286A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
PH12015500860A1 (en) 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
IN2012DN03182A (en)
MX2011010451A (en) Oxadiazole derivatives.
MX2011013648A (en) New compounds, pharmaceutical composition and methods relating thereto.
MX2012012328A (en) Pyrazole compounds as jak inhibitors.
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
MX2013000474A (en) Novel arylamide derivatives having antiandrogenic properties.
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
IL202236A0 (en) Prolinamide derivatives as nk3 antagonists
MX2013006420A (en) Hydroxylated aminotriazole derivatives as alx receptor agonists.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10730867

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10730867

Country of ref document: EP

Kind code of ref document: A1